Grand Pharmaceutical Group Limited

SEHK:512 Stock Report

Market Cap: HK$16.8b

Grand Pharmaceutical Group Future Growth

Future criteria checks 2/6

Grand Pharmaceutical Group is forecast to grow earnings and revenue by 17.3% and 8.8% per annum respectively. EPS is expected to grow by 17% per annum. Return on equity is forecast to be 11.2% in 3 years.

Key information

17.3%

Earnings growth rate

16.96%

EPS growth rate

Pharmaceuticals earnings growth15.6%
Revenue growth rate8.8%
Future return on equity11.24%
Analyst coverage

Low

Last updated12 May 2026

Recent future growth updates

Analysis Article • Mar 30

Grand Pharmaceutical Group Limited Just Missed EPS By 42%: Here's What Analysts Think Will Happen Next

It's been a good week for Grand Pharmaceutical Group Limited ( HKG:512 ) shareholders, because the company has just...

Recent updates

Analysis Article • Mar 30

Grand Pharmaceutical Group Limited Just Missed EPS By 42%: Here's What Analysts Think Will Happen Next

It's been a good week for Grand Pharmaceutical Group Limited ( HKG:512 ) shareholders, because the company has just...
Analysis Article • Oct 03

These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Reasonably Well

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Sep 15

What Grand Pharmaceutical Group Limited's (HKG:512) P/E Is Not Telling You

With a price-to-earnings (or "P/E") ratio of 14.8x Grand Pharmaceutical Group Limited ( HKG:512 ) may be sending...
Analysis Article • Jul 17

With EPS Growth And More, Grand Pharmaceutical Group (HKG:512) Makes An Interesting Case

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Analysis Article • May 12

Grand Pharmaceutical Group Limited (HKG:512) Stock Rockets 41% As Investors Are Less Pessimistic Than Expected

Grand Pharmaceutical Group Limited ( HKG:512 ) shares have continued their recent momentum with a 41% gain in the last...
Analysis Article • Apr 03

Grand Pharmaceutical Group Limited's (HKG:512) CEO Compensation Looks Acceptable To Us And Here's Why

Key Insights Grand Pharmaceutical Group will host its Annual General Meeting on 10th of April Total pay for CEO Chao...
Analysis Article • Mar 25

Additional Considerations Required While Assessing Grand Pharmaceutical Group's (HKG:512) Strong Earnings

Unsurprisingly, Grand Pharmaceutical Group Limited's ( HKG:512 ) stock price was strong on the back of its healthy...
Analysis Article • Feb 24

Little Excitement Around Grand Pharmaceutical Group Limited's (HKG:512) Earnings

When close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") above 11x, you may consider...
Analysis Article • Sep 19

Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough

When close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") above 9x, you may consider...
Analysis Article • Jun 05

Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Grand Pharmaceutical Group Limited ( HKG:512 ) will increase its dividend from last year's comparable payment on the...
Analysis Article • May 22

Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings

There wouldn't be many who think Grand Pharmaceutical Group Limited's ( HKG:512 ) price-to-earnings (or "P/E") ratio of...
Analysis Article • Apr 25

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Grand Pharmaceutical Group Limited ( HKG:512 ) has announced that it will be increasing its dividend from last year's...
Analysis Article • Mar 25

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Grand Pharmaceutical Group Limited ( HKG:512 ) will increase its dividend from last year's comparable payment on the...
Analysis Article • Oct 20

We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Sep 26

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Analysis Article • Jun 04

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14

Grand Pharmaceutical Group Limited's ( HKG:512 ) dividend will be increasing from last year's payment of the same...

Earnings and Revenue Growth Forecasts

SEHK:512 - Analysts future estimates and past financials data (HKD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202815,9672,2342,1322,7723
12/31/202714,7832,0861,9942,5954
12/31/202613,4701,9131,8342,3464
12/31/202512,2831,2411271,650N/A
9/30/202511,9941,6606111,698N/A
6/30/202511,7052,0791,0941,747N/A
3/31/202511,6752,2741,1981,823N/A
12/31/202411,6452,4681,3011,898N/A
9/30/202411,1162,4381,3761,900N/A
6/30/202410,5872,4091,4511,903N/A
3/31/202410,5582,1441,6942,164N/A
12/31/202310,5301,8801,9372,425N/A
9/30/202310,4342,1391,3492,114N/A
6/30/202310,3392,3987611,804N/A
3/31/20239,9512,2397731,823N/A
12/31/20229,5622,0797851,843N/A
9/30/20229,4031,9951,0681,829N/A
6/30/20229,2441,9101,3501,815N/A
3/31/20228,9212,1561,4101,911N/A
12/31/20218,5982,4031,4692,006N/A
9/30/20218,1312,3401,4872,001N/A
6/30/20217,6642,2771,5041,995N/A
3/31/20217,0082,0351,3511,726N/A
12/31/20206,3531,7931,1971,456N/A
9/30/20206,3061,5581,0201,400N/A
6/30/20206,2591,3238431,345N/A
3/31/20206,4251,2377901,324N/A
12/31/20196,5911,1517371,304N/A
9/30/20196,4501,048N/A1,661N/A
6/30/20196,309944N/A2,017N/A
3/31/20196,134828N/A1,713N/A
12/31/20185,958713N/A1,408N/A
9/30/20185,845642N/A898N/A
6/30/20185,732570N/A387N/A
3/31/20185,251516N/A553N/A
12/31/20174,771461N/A720N/A
9/30/20174,480413N/A708N/A
6/30/20174,190364N/A696N/A
3/31/20173,943317N/A736N/A
12/31/20163,696269N/A775N/A
9/30/20163,573241N/A807N/A
6/30/20163,450213N/A839N/A
3/31/20163,348197N/A668N/A
12/31/20153,246181N/A496N/A
9/30/20153,158187N/A439N/A
6/30/20153,071194N/A382N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 512's forecast earnings growth (17.3% per year) is above the savings rate (3%).

Earnings vs Market: 512's earnings (17.3% per year) are forecast to grow faster than the Hong Kong market (12.8% per year).

High Growth Earnings: 512's earnings are forecast to grow, but not significantly.

Revenue vs Market: 512's revenue (8.8% per year) is forecast to grow slower than the Hong Kong market (8.9% per year).

High Growth Revenue: 512's revenue (8.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 512's Return on Equity is forecast to be low in 3 years time (11.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/19 13:35
End of Day Share Price 2026/06/18 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Grand Pharmaceutical Group Limited is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullChina International Capital Corporation Limited
Yanyin ZhuChina International Capital Corporation Limited
Zhu ChenCitic Securities Co., Ltd.